




Figure 1: Chemical Structures of Illustrative Nucleosides




β -D-2'-CH₃-riboG




β -D-2'-CH₃-riboC




β -D-2'-CH₃-riboU




β -D-2'-CH₃-riboA




β -D-2'-CH₃-riboI




β -D-2'-CH₃-riboT




β -D-1'-CH₃-riboA



β -D-1'-CH₃-riboG



FIAU



Ribavirin

Figure 2: Screening Pharmacokinetics of β -D-2'-CH₃-riboG in Cynomolgus Monkeys




Figure 3: Pharmacokinetics of β -D-2'-CH₃-riboG in Cynomolgus Monkeys




Figure 3a






Figure 3b

Figure 4: BVDV Cell Protection Assay (CPA) Of β -D-2'-CH₃-riboG



Cell Protection Assay






Figure 5: BVDV Cell Protection Assay (CPA) of Ribavirin



Cell Protection Assay




Figure 6: BVDV Cell Protection Assays




Figure 7: Plaque Purified BVDV




Figure 8: BVDV Plaque Assay of $\beta\text{-D-2'-CH}_3\text{-riboU}$





Figure 9: Yield Reduction Assay of β -D-2'-CH₃-riboG



4-log virus reduction at 9 μ M


Figure 10: BVDV Yield Reduction Assay for β -D-2'-CH₃-riboC

0 μ M



No
Virus

0.5 μ M



2.7 μ M

0.8 μ M

4 μ M

1.2 μ M

6 μ M

1.5 μ M

9 μ M